Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.48 |
| ▸ | GSK3B | P49841 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | NFATC1 | O95644 | 3/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.42 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GABRP | O00591 | 1/20 | 0.40 |
| ▸ | GABRD | O14764 | 1/20 | 0.40 |
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | CHUK | O15111 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | TOP1 | P11387 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26696387 | 0.87 | CYP17A1 (0.45) | MAPTDYRK1AGSK3BNFATC1PDPK1 | |
| SCHEMBL26696355 | 0.85 | DYRK1A (0.42) | MAPTDYRK1AGSK3BNFATC1PDPK1 | |
| SCHEMBL26696388 | 0.85 | DYRK1A (0.42) | MAPTDYRK1AGSK3BNFATC1PDPK1 | |
| SCHEMBL26696337 | 0.85 | DYRK1A (0.43) | MAPTDYRK1AGSK3BNFATC1PDPK1 | |
| SCHEMBL26873731 | 0.84 | MAPT (0.48) | MAPTDYRK1AGSK3BSMN1; SMN2NFATC1 | |
| SCHEMBL26696378 | 0.84 | MGAM (0.44) | MAPTDYRK1AGSK3BNFATC1PDPK1 | |
| SCHEMBL1992184 | 0.81 | MAPT (0.61) | MAPTGAAALDH1A1GPR84NOD2 | |
| SCHEMBL13763231 | 0.80 | MAPT (0.59) | MAPTSMN1; SMN2GAAGPR84NOD2 | |
| SCHEMBL26696364 | 0.80 | CA12 (0.39) | MAPTDYRK1AGSK3BNFATC1GAA | |
| SCHEMBL3218993 | 0.79 | MGAM (0.55) | MAPTDYRK1AGSK3BGAAHAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382926-A1 | COMPOUNDS AND USES THEREOF | THE UNIVERSITY OF THE WEST INDIES (TT) | 2023-11-30 | — | — | US | disclosed |
| US-20230382926-A1 | COMPOUNDS AND USES THEREOF | THE UNIVERSITY OF THE WEST INDIES (TT) | 2023-11-30 | — | — | US | disclosed |
| US-7608627-B2 | I kappa B kinase inhibition; diabetes; (7-Chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)methanol; N-Benzyl-7-chloro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-27 | — | — | US | disclosed |
| US-7608627-B2 | I kappa B kinase inhibition; diabetes; (7-Chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)methanol; N-Benzyl-7-chloro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-27 | — | — | US | disclosed |
| US-7608627-B2 | I kappa B kinase inhibition; diabetes; (7-Chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)methanol; N-Benzyl-7-chloro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-27 | — | — | US | disclosed |
| US-20080064715-A1 | 6-Azaindole Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-03-13 | — | — | US | disclosed |
| US-20080064715-A1 | 6-Azaindole Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-03-13 | — | — | US | disclosed |
| US-20080064715-A1 | 6-Azaindole Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382926-A1 | COMPOUNDS AND USES THEREOF | CFTR, CCL11, CEL | MAPT 1613/4885DYRK1A 4777/4885GSK3B 3759/4885 |
| US-20080064715-A1 | 6-Azaindole Compound | RELA, NFKBIA, GPR119 | MAPT 4532/4885DYRK1A 1278/4885GSK3B 813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.